Durvalumab consolidation post-CRT (LS-SCLC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-DURVALUMAB |
|---|
| ID | REG-DURVA-CONSOLIDATION-SCLC |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ADRIATIC-CHENG-2024 SRC-NCCN-SCLC-2025 |
Notes
ADRIATIC (Cheng NEJM 2024, NCT03703297): durvalumab 1500 mg q4w consolidation × up to 24 months in LS-SCLC patients without progression after concurrent platinum-based CRT — mOS 55.9 vs 33.4 months (HR 0.73; p=0.01); mPFS 16.6 vs 9.2 months (HR 0.76; p=0.02). First major OS-positive trial in LS-SCLC in decades. FDA approval Dec-2024; new standard of care. Tremelimumab arm (durva+treme) did not improve outcomes vs durva alone — durva monotherapy is the approved consolidation regimen.
Used By
Indication
IND-SCLC-LS-CONSOLIDATION-DURVA- IND-SCLC-LS-CONSOLIDATION-DURVA